Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Lazertinib in Hepatic Impairment
NCT05112952Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of lazertinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Plasma Concentrations of Lazertinib. Started Nov 2021; status: completed.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05112952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05112952.